Pharmaceutical Research Center

药物研究中心

• 批准号: 8120820
• 负责人: KARAM F.A. SOLIMAN
• 金额: $ 234.09万
• 依托单位: FLORIDA AGRICULTURAL AND MECHANICAL UNIV
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-08-01 至 2013-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8120820
• 关键词: Pharmaceutical; Research; Center

DESCRIPTION (provided by applicant): Pharmaceutical Research Center: This application seeks to continue the evolution of the Pharmaceutical Research Center at Florida A&M University (FAMU). The previously funded targeted research activities have demonstrated productivity and resulted in significant discoveries that have led to the award of several patents and additional pending discoveries. Based on the evaluation of the current research infrastructure and the strategic needs of the program, it is proposed to transition the targeted activities into the development of Core research facilities. The main objective of the current application is to build the infrastructure of the research program towards more understanding of the mechanistic details of the molecular system. This RCMI center will focus efforts on approaches, i.e., gene expression analysis, proteomics, PCR analysis, gene delivery systems and DNA picroarray techniques. The establishment of Core facilities in the areas of molecular neurobiology, cellular imaging, neurochemistry/receptors, flow cytometry and nanomedicine will increase our abilities to understand the mechanistic details of the molecular system and to provide greater insights into how the different molecular are modulated under disease and adverse conditions. The Pharmaceutical Research Center will consist of a research administrative component coupled with four (4) core service delivery facilities. The administrative component will continue to provide pre- and post- award assistance, coordinate the activities of the external and internal advisory committee, provide scientific seminars and grants workshops, coordinate a new structured mentoring program, facilitate an extensive external evaluation of program outcomes, assist in faculty development, hire a research faculty member and market and conduct an on-site grants management workshop and the annual RCMI R01 Scientist Seminar Series. Specific aim one (1) is to transition the program from the current research programs in neuroscience, drug delivery, and molecular biology to research cores focusing on Neurodegeneration research, Nanomedicine research, drug discovery and biotechnology: pathways to disease prevention and therapy. Through this network of Core facilities, the Pharmaceutical Research Center will foster inter- and inter-disciplinary research. Aim two (2) is to increase research investigators capabilities and competitiveness to receive four (4) investigators initiated grants. Aim three (3) is to assure the completion of program objectives and outcomes through a comprehensive formative and summative evaluation process. Aim four (4) is to address health disparities through research emphasis on those conditions that adversely impact disadvantaged populations and produce additional minority scientists who will address disparities. This RCMI Program has been transformational at FAMU. Ensuring translational research is at the forefront of the proposed research activities as we seek to accelerate the utilization of our biomedical discoveries. The College's motto is "Funding Cures and Saving Lives."

描述（由申请人提供）：制药研究中心：该申请旨在继续佛罗里达农工大学（FAMU）的药物研究中心的发展。先前资助的有针对性的研究活动已经证明了生产力，并导致了重大发现，从而授予了几项专利和其他未决的发现。根据对当前研究基础设施和计划的战略需求的评估，建议将目标活动转变为核心研究设施的发展。当前应用的主要目的是建立研究计划的基础设施，以更多地了解分子系统的机械细节。这个RCMI中心将重点放在方法上，即基因表达分析，蛋白质组学，PCR分析，基因输送系统和DNA Picroarray技术。在分子神经生物学，细胞成像，神经化学/受体，流式细胞术和纳米医学领域的核心设施建立将提高我们的能力，以了解分子系统的机理细节，并提供更大的见解，以提供在疾病和不良条件下如何调节不同分子的能力。药物研究中心将由研究管理组成部分以及四（4）个核心服务提供机构组成。 The administrative component will continue to provide pre- and post- award assistance, coordinate the activities of the external and internal advisory committee, provide scientific seminars and grants workshops, coordinate a new structured mentoring program, facilitate an extensive external evaluation of program outcomes, assist in faculty development, hire a research faculty member and market and conduct an on-site grants management workshop and the annual RCMI R01 Scientist Seminar Series.具体目的一（1）是将该程序从当前的神经科学，药物输送和分子生物学的研究计划转变为关注神经退行性研究，纳米医学研究，药物发现和生物技术的研究核心：预防疾病和治疗的途径。通过这个核心设施网络，制药研究中心将培养跨学科研究。目标两（2）是提高研究人员的能力和竞争力，以获得四（4）个调查人员的赠款。目标三（3）是通过全面的形成性和总结性评估过程来确保计划目标和成果的完成。目标四（4）是通过研究强调那些不利影响弱势群体并产生其他将解决差异的少数族裔科学家来解决健康差异的问题。该RCMI计划在FAMU方面具有变革性。当我们试图加速生物医学发现的利用时，确保转化研究处于拟议研究活动的最前沿。该学院的座右铭是“筹集资金并挽救生命”。

项目成果

Efficacy of aerosolized celecoxib encapsulated nanostructured lipid carrier in non-small cell lung cancer in combination with docetaxel.

• DOI: 10.1007/s11095-013-0984-9
• 发表时间: 2013-05
• 期刊: PHARMACEUTICAL RESEARCH
• 影响因子: 3.7
• 作者: Patel, Apurva R.;Chougule, Mahavir B.;Townley, I;Patlolla, Ram;Wang, Guangdi;Singh, Mandip
• 通讯作者: Singh, Mandip

The Mechanistic Targets of Antifungal Agents: An Overview.

• DOI: 10.2174/1389557516666160118112103
• 发表时间: 2016
• 期刊: Mini reviews in medicinal chemistry
• 作者: Mazu TK;Bricker BA;Flores-Rozas H;Ablordeppey SY
• 通讯作者: Ablordeppey SY

The role of intracellular glutathione in inorganic mercury-induced toxicity in neuroblastoma cells.

• DOI: 10.1007/s11064-009-9962-3
• 发表时间: 2009-09
• 期刊: NEUROCHEMICAL RESEARCH
• 影响因子: 4.4
• 作者: Becker, Alan;Soliman, Karam F. A.
• 通讯作者: Soliman, Karam F. A.

Prostate cancer disparities in Black men of African descent: a comparative literature review of prostate cancer burden among Black men in the United States, Caribbean, United Kingdom, and West Africa.

• DOI: 10.1186/1750-9378-4-s1-s2
• 发表时间: 2009-02-10
• 期刊: Infectious agents and cancer
• 影响因子: 3.7
• 作者: Odedina FT;Akinremi TO;Chinegwundoh F;Roberts R;Yu D;Reams RR;Freedman ML;Rivers B;Green BL;Kumar N
• 通讯作者: Kumar N

Whole genome expression profile in neuroblastoma cells exposed to 1-methyl-4-phenylpyridine.

• DOI: 10.1016/j.neuro.2012.06.009
• 发表时间: 2012-10
• 期刊: Neurotoxicology
• 影响因子: 3.4
• 作者: Mazzio E;Soliman KF
• 通讯作者: Soliman KF